Section 11: Evaluation and Management of Patients with Heart Failure and Preserved Left Ventricular Ejection Fraction

Journal of Cardiac Failure

Volumn 16, Issue 6, 2010, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; IRBESARTAN; LOOP DIURETIC AGENT; NEBIVOLOL; PERINDOPRIL; RAMIPRIL; THIAZIDE DIURETIC AGENT; VERAPAMIL;

ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD PRESSURE MONITORING; DIFFERENTIAL DIAGNOSIS; DIURETIC THERAPY; DRUG EFFECT; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MORBIDITY; MORTALITY; MYOCARDIAL PERFUSION IMAGING; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; RADIOISOTOPE VENTRICULOGRAPHY; SODIUM RESTRICTION; THORAX RADIOGRAPHY; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 77953566283     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2010.05.020     Document Type: Article

References (56)

1. Gaasch W.H. Diagnosis and treatment of heart failure based on left ventricular systolic or diastolic dysfunction. JAMA 271 (1994) 1276-1280
2. Smith G.L., Masoudi F.A., Vaccarino V., Radford M.J., and Krumholz H.M. Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline. J Am Coll Cardiol 41 (2003) 1510-1518
3. Swedberg K., Cleland J., Dargie H., Drexler H., Follath F., Komajda M., et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26 (2005) 1115-1140
4. Konstam M.A. "Systolic and diastolic dysfunction" in heart failure? Time for a new paradigm. J Card Fail 9 (2003) 1-3
5. Vasan R.S., Benjamin E.J., and Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol 26 (1995) 1565-1574
6. Zile M.R., and Brutsaert D.L. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation 105 (2002) 1503-1508
7. Zile M.R. Heart failure with preserved ejection fraction: is this diastolic heart failure?. J Am Coll Cardiol 41 (2003) 1519-1522
8. Arnold J.M., Liu P., Demers C., Dorian P., Giannetti N., Haddad H., et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol 22 (2006) 23-45
9. Dickstein K., Cohen-Solal A., Filippatos G., McMurray J.J., Ponikowski P., Poole-Wilson P.A., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 29 (2008) 2388-2442
10. Hunt S.A., Abraham W.T., Chin M.H., Feldman A.M., Francis G.S., Ganiats T.G., et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 53 (2009) e1-90
11. Pearlman E.S., Weber K.T., Janicki J.S., Pietra G.G., and Fishman A.P. Muscle fiber orientation and connective tissue content in the hypertrophied human heart. Lab Invest 46 (1982) 158-164
12. Huysman J.A., Vliegen H.W., Van der Laarse A., and Eulderink F. Changes in nonmyocyte tissue composition associated with pressure overload of hypertrophic human hearts. Pathol Res Pract 184 (1989) 577-581
13. Gwathmey J.K., Copelas L., MacKinnon R., Schoen F.J., Feldman M.D., Grossman W., et al. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res 61 (1987) 70-76
14. Philbin E.F., Rocco Jr. T.A., Lindenmuth N.W., Ulrich K., and Jenkins P.L. Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. Am J Med 109 (2000) 605-613
15. Senni M., Tribouilloy C.M., Rodeheffer R.J., Jacobsen S.J., Evans J.M., Bailey K.R., et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 98 (1998) 2282-2289
16. Vasan R.S., Larson M.G., Benjamin E.J., Evans J.C., Reiss C.K., and Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 33 (1999) 1948-1955
17. Chen H.H., Lainchbury J.G., Senni M., Bailey K.R., and Redfield M.M. Diastolic heart failure in the community: clinical profile, natural history, therapy, and impact of proposed diagnostic criteria. J Card Fail 8 (2002) 279-287
18. Senni M., and Redfield M.M. Heart failure with preserved systolic function. A different natural history?. J Am Coll Cardiol 38 (2001) 1277-1282
19. McDermott M.M., Feinglass J., Lee P.I., Mehta S., Schmitt B., Lefevre F., et al. Systolic function, readmission rates, and survival among consecutively hospitalized patients with congestive heart failure. Am Heart J 134 (1997) 728-736
20. Devereux R.B., Roman M.J., Liu J.E., Welty T.K., Lee E.T., Rodeheffer R., et al. Congestive heart failure despite normal left ventricular systolic function in a population-based sample: the Strong Heart Study. Am J Cardiol 86 (2000) 1090-1096
21. Jones R.C., Francis G.S., and Lauer M.S. Predictors of mortality in patients with heart failure and preserved systolic function in the Digitalis Investigation Group trial. J Am Coll Cardiol 44 (2004) 1025-1029
22. Judge K.W., Pawitan Y., Caldwell J., Gersh B.J., and Kennedy J.W. Congestive heart failure symptoms in patients with preserved left ventricular systolic function: analysis of the CASS registry. J Am Coll Cardiol 18 (1991) 377-382
23. Maisel A.S., Krishnaswamy P., Nowak R.M., McCord J., Hollander J.E., Duc P., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347 (2002) 161-167
24. Yamamoto K., Burnett Jr. J.C., Jougasaki M., Nishimura R.A., Bailey K.R., Saito Y., et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 28 (1996) 988-994
25. Maisel A.S., McCord J., Nowak R.M., Hollander J.E., Wu A.H., Duc P., et al. Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 41 (2003) 2010-2017
26. Massie B.M. Natriuretic peptide measurements for the diagnosis of "nonsystolic" heart failure: good news and bad. J Am Coll Cardiol 41 (2003) 2018-2021
27. Reichek N., and Devereux R.B. Left ventricular hypertrophy: relationship of anatomic, echocardiographic and electrocardiographic findings. Circulation 63 (1981) 1391-1398
28. Maron B.J. Hypertrophic cardiomyopathy. Lancet 350 (1997) 127-133
29. Marian A.J., and Roberts R. Recent advances in the molecular genetics of hypertrophic cardiomyopathy. Circulation 92 (1995) 1336-1347
30. Kyle R.A., and Greipp P.R. Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin Proc 58 (1983) 665-683
31. Kyle R.A., Gertz M.A., Greipp P.R., Witzig T.E., Lust J.A., Lacy M.Q., et al. Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood 93 (1999) 1062-1066
32. Sharma O.P., Maheshwari A., and Thaker K. Myocardial sarcoidosis. Chest 103 (1993) 253-258
33. Arnett E.N., Nienhuis A.W., Henry W.L., Ferrans V.J., Redwood D.R., and Roberts W.C. Massive myocardial hemosiderosis: a structure-function conference at the National Heart and Lung Institute. Am Heart J 90 (1975) 777-787
34. Angelini A., Calzolari V., Thiene G., Boffa G.M., Valente M., Daliento L., et al. Morphologic spectrum of primary restrictive cardiomyopathy. Am J Cardiol 80 (1997) 1046-1050
35. Karia D.H., Xing Y.Q., Kuvin J.T., Nesser H.J., and Pandian N.G. Recent role of imaging in the diagnosis of pericardial disease. Curr Cardiol Rep 4 (2002) 33-40
36. Yusuf S., Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362 (2003) 777-781
37. Massie B.M., Carson P.E., McMurray J.J., Komajda M., McKelvie R., Zile M.R., et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359 (2008) 2456-2467
38. Arnold J.M., Yusuf S., Young J., Mathew J., Johnstone D., Avezum A., et al. Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 107 (2003) 1284-1290
39. Fox K.M. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 (2003) 782-788
40. Alvares R.F., and Goodwin J.F. Non-invasive assessment of diastolic function in hypertrophic cardiomyopathy on and off beta adrenergic blocking drugs. Br Heart J 48 (1982) 204-212
41. Aroesty J.M., McKay R.G., Heller G.V., Royal H.D., Als A.V., and Grossman W. Simultaneous assessment of left ventricular systolic and diastolic dysfunction during pacing-induced ischemia. Circulation 71 (1985) 889-900
42. Redfield M.M., Kay G.N., Jenkins L.S., Mianulli M., Jensen D.N., and Ellenbogen K.A. Tachycardia-related cardiomyopathy: a common cause of ventricular dysfunction in patients with atrial fibrillation referred for atrioventricular ablation. Mayo Clin Proc 75 (2000) 790-795
43. Grogan M., Smith H.C., Gersh B.J., and Wood D.L. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 69 (1992) 1570-1573
44. Flather M.D., Shibata M.C., Coats A.J., van Veldhuisen D.J., Parkhomenko A., Borbola J., et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26 (2005) 215-225
45. van Veldhuisen D.J., Cohen-Solal A., Bohm M., Anker S.D., Babalis D., Roughton M., et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 53 (2009) 2150-2158
46. He K.L., Burkhoff D., Leng W.X., Liang Z.R., Fan L., Wang J., et al. Comparison of ventricular structure and function in Chinese patients with heart failure and ejection fractions >55% versus 40% to 55% versus <40%. Am J Cardiol 103 (2009) 845-851
47. Fonarow G.C., Stough W.G., Abraham W.T., Albert N.M., Gheorghiade M., Greenberg B.H., et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 50 (2007) 768-777
48. Sweitzer N.K., Lopatin M., Yancy C.W., Mills R.M., and Stevenson L.W. Comparison of clinical features and outcomes of patients hospitalized with heart failure and normal ejection fraction (> or =55%) versus those with mildly reduced (40% to 55%) and moderately to severely reduced (<40%) fractions. Am J Cardiol 101 (2008) 1151-1156
49. Grossman W. Diastolic dysfunction in congestive heart failure. N Engl J Med 325 (1991) 1557-1564
50. Bonow R.O., Dilsizian V., Rosing D.R., Maron B.J., Bacharach S.L., and Green M.V. Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects. Circulation 72 (1985) 853-864
51. Brodsky S.J., Cutler S.S., Weiner D.A., McCabe C.H., Ryan T.J., and Klein M.D. Treatment of stable angina of effort with verapamil: a double-blind, placebo-controlled randomized crossover study. Circulation 66 (1982) 569-574
52. Chen C.H., Nakayama M., Talbot M., Nevo E., Fetics B., Gerstenblith G., et al. Verapamil acutely reduces ventricular-vascular stiffening and improves aerobic exercise performance in elderly individuals. J Am Coll Cardiol 33 (1999) 1602-1609
53. Pedersen O.D., Bagger H., Keller N., Marchant B., Kober L., and Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation 104 (2001) 292-296
54. Torp-Pedersen C., Moller M., Bloch-Thomsen P.E., Kober L., Sandoe E., Egstrup K., et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 341 (1999) 857-865
55. Deedwania P.C., Singh B.N., Ellenbogen K., Fisher S., Fletcher R., and Singh S.N. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation 98 (1998) 2574-2579
56. Hsu L.F., Jais P., Sanders P., Garrigue S., Hocini M., Sacher F., et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 351 (2004) 2373-2383